Cancer stem cells - Important players in tumor therapy resistance

FEBS Journal

Volumn 281, Issue 21, 2014, Pages 4779-4791

  Colak, Selcuk ^a   Medema, Jan P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Cancer; Cancer stem cell; Chemotherapy; Resistance; Tumor initiating cells

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; ANTINEOPLASTIC AGENT; BH3 PROTEIN; BONE MORPHOGENETIC PROTEIN; CD133 ANTIBODY; CD133 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CD47 ANTIBODY; CUR 199691; CXCR1 ANTIBODY; CYTARABINE; DLL4 ANTIBODY; ENZYME INHIBITOR; GEMCITABINE; IRINOTECAN; NAVITOCLAX; NOTCH RECEPTOR; OXALIPLATIN; PROTEIN BCL 2; PROTEIN BCL XL; SALUBRINAL; SB 218078; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; VENETOCLAX; WEE1; WNT PROTEIN; DIFFERENTIATION ANTIGEN; DNA; MONOCLONAL ANTIBODY; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FATE; CELL KILLING; CELL PROTECTION; CELL RENEWAL; CELL SURVIVAL; COLORECTAL CANCER; DNA REPAIR; DRUG TARGETING; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; INTRACELLULAR SIGNALING; MOLECULAR DYNAMICS; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; RADIOSENSITIVITY; WNT SIGNALING PATHWAY; ANIMAL; DRUG DESIGN; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; MOLECULARLY TARGETED THERAPY; MOUSE; NEOPLASMS; PATHOLOGY; PHYSIOLOGY; RADIATION DOSE; RADIATION RESPONSE; RECURRENT DISEASE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, DIFFERENTIATION; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; DNA REPAIR; DNA, NEOPLASM; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HETEROGRAFTS; HUMANS; MICE; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASTIC STEM CELLS; RADIATION TOLERANCE; RECEPTORS, NOTCH; RECURRENCE; WNT SIGNALING PATHWAY;

EID: 84915749487     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13023     Document Type: Article

References (117)

1. Weinhouse S (1972) National Cancer Act of 1971-an editorial. Cancer Res 32, i-ii.
2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM & Forman DBF (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer, Lyon, France. Available at: http://globocan.iarc.fr (Accessed June 2014).
3. Holohan C, Van Schaeybroeck S, Longley DB & Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13, 714-726.
4. Gottesman MM, Fojo T & Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2, 48-58.
5. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL & Wahl GM (2006) Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66, 9339-9344.
6. Medema JP (2013) Cancer stem cells: the challenges ahead. Nat Cell Biol 15, 338-344.
7. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA & Dick JE (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645-648.
8. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C & De Maria R (2007) Identification and expansion of human colon-cancerinitiating cells. Nature 445, 111-115.
9. O'Brien CA, Pollett A, Gallinger S & Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106-110.
10. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD & Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432, 396-401.
11. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ & Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100, 3983-3988.
12. Collins AT, Berry PA, Hyde C, Stower MJ & Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65, 10946-10951.
13. Kelly PN, Dakic A, Adams JM, Nutt SL & Strasser A (2007) Tumor growth need not be driven by rare cancer stem cells. Science 317, 337.
14. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM & Morrison SJ (2008) Efficient tumour formation by single human melanoma cells. Nature 456, 593-598.
15. Meacham CE & Morrison SJ (2013) Tumour heterogeneity and cancer cell plasticity. Nature 501, 328-337.
16. Magee JA, Piskounova E & Morrison SJ (2012) Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21, 283-296.
17. Blanpain C, Horsley V & Fuchs E (2007) Epithelial stem cells: turning over new leaves. Cell 128, 445-458.
18. Medema JP & Vermeulen L (2011) Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. Nature 474, 318-326.
19. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, Hintz L, Nusse R & Weissman IL (2003) A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 423, 409-414.
20. Zeng YA & Nusse R (2010) Wnt proteins are selfrenewal factors for mammary stem cells and promote their long-term expansion in culture. Cell Stem Cell 6, 568-577.
21. Kuhnert F, Davis CR, Wang HT, Chu P, Lee M, Yuan J, Nusse R & Kuo CJ (2004) Essential requirement for Wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression of Dickkopf-1. Proc Natl Acad Sci USA 101, 266-271.
22. Duncan AW, Rattis FM, DiMascio LN, Congdon KL, Pazianos G, Zhao C, Yoon K, Cook JM, Willert K, Gaiano N et al. (2005) Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat Immunol 6, 314-322.
23. Bhardwaj G, Murdoch B, Wu D, Baker DP, Williams KP, Chadwick K, Ling LE, Karanu FN & Bhatia M (2001) Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat Immunol 2, 172-180.
24. Lai K, Kaspar BK, Gage FH & Schaffer DV (2003) Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo. Nat Neurosci 6, 21-27.
25. Haramis AP, Begthel H, van den Born M, van Es J, Jonkheer S, Offerhaus GJ & Clevers H (2004) De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine. Science 303, 1684-1686.
26. He XC, Zhang J, Tong WG, Tawfik O, Ross J, Scoville DH, Tian Q, Zeng X, He X, Wiedemann LM et al. (2004) BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. Nat Genet 36, 1117-1121.
27. Jamora C, DasGupta R, Kocieniewski P & Fuchs E (2003) Links between signal transduction, transcription and adhesion in epithelial bud development. Nature 422, 317-322.
28. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA & Lander ES (2009) Identification of selective inhibitors of cancer stem cells by highthroughput screening. Cell 138, 645-659.
29. Malanchi I, Peinado H, Kassen D, Hussenet T, Metzger D, Chambon P, Huber M, Hohl D, Cano A, Birchmeier W et al. (2008) Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 452, 650-653.
30. Teng Y, Wang X, Wang Y & Ma D (2010) Wnt/betacatenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem Biophys Res Commun 392, 373-379.
31. Vermeulen L, De Sousa EMF, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H et al. (2010) Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12, 468-476.
32. Lu D, Choi MY, Yu J, Castro JE, Kipps TJ & Carson DA (2011) Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci USA 108, 13253-13257.
33. Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, Fitch-Bruhns M, Lazetic S, Park IK, Sato A et al. (2009) DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 5, 168-177.
34. Sikandar SS, Pate KT, Anderson S, Dizon D, Edwards RA, Waterman ML & Lipkin SM (2010) NOTCH signaling is required for formation and selfrenewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res 70, 1469-1478.
35. Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N, Koh C, Zhang J, Li YM, Maciaczyk J et al. (2010) NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 28, 5-16.
36. Prasetyanti PR, Zimberlin CD, Bots M, Vermeulen L, Melo Fde S & Medema JP (2013) Regulation of stem cell self-renewal and differentiation by Wnt and Notch are conserved throughout the adenoma-carcinoma sequence in the colon. Mol Cancer 12, 126.
37. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW, Suri P & Wicha MS (2006) Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 66, 6063-6071.
38. Varnat F, Duquet A, Malerba M, Zbinden M, Mas C, Gervaz P & Ruiz i Altaba A (2009) Human colon cancer epithelial cells harbour active HEDGEHOGGLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med 1, 338-351.
39. Justilien V, Walsh MP, Ali SA, Thompson EA, Murray NR & Fields AP (2014) The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell 25, 139-151.
40. Myllyperkio MH & Vilpo JA (1999) Increased DNA single-strand break joining activity in UV-irradiated CD34+ versus CD34-bone marrow cells. Mutat Res 425, 169-176.
41. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD & Rich JN (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760.
42. Friedmann-Morvinski D, Bushong EA, Ke E, Soda Y, Marumoto T, Singer O, Ellisman MH & Verma IM (2012) Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 338, 1080-1084.
43. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C & Lander ES (2011) Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146, 633-644.
44. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y, Polyak K et al. (2011) Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 108, 7950-7955.
45. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J & Buck DW (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90, 5002-5012.
46. Zhu L, Gibson P, Currle DS, Tong Y, Richardson RJ, Bayazitov IT, Poppleton H, Zakharenko S, Ellison DW & Gilbertson RJ (2009) Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 457, 603-607.
47. Snippert HJ, van Es JH, van den Born M, Begthel H, Stange DE, Barker N & Clevers H (2009) Prominin-1/CD133 marks stem cells and early progenitors in mouse small intestine. Gastroenterology 136, 2187-2194 e1.
48. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ & Heeschen C (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313-323.
49. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegebarth A, Korving J, Begthel H, Peters PJ et al. (2007) Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449, 1003-1007.
50. Barker N, Tan S & Clevers H (2013) Lgr proteins in epithelial stem cell biology. Development 140, 2484-2494.
51. Barker N, Huch M, Kujala P, van de Wetering M, Snippert HJ, van Es JH, Sato T, Stange DE, Begthel H, van den Born M et al. (2010) Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell 6, 25-36.
52. Jaks V, Barker N, Kasper M, van Es JH, Snippert HJ, Clevers H & Toftgard R (2008) Lgr5 marks cycling, yet long-lived, hair follicle stem cells. Nat Genet 40, 1291-1299.
53. Kemper K, Prasetyanti PR, De Lau W, Rodermond H, Clevers H & Medema JP (2012) Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells. Stem Cells 30, 2378-2386.
54. Hirsch D, Barker N, McNeil N, Hu Y, Camps J, McKinnon K, Clevers H, Ried T & Gaiser T (2014) LGR5 positivity defines stem-like cells in colorectal cancer. Carcinogenesis 35, 849-858.
55. Chute JP, Muramoto GG, Whitesides J, Colvin M, Safi R, Chao NJ & McDonnell DP (2006) Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci USA 103, 11707-11712.
56. Ginestier C, Wicinski J, Cervera N, Monville F, Finetti P, Bertucci F, Wicha MS, Birnbaum D & Charafe-Jauffret E (2009) Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle 8, 3297-3302.
57. Ma I & Allan AL (2011) The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev 7, 292-306.
58. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S et al. (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555-567.
59. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS & Boman BM (2009) Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 69, 3382-3389.
60. Colak S, Zimberlin CD, Fessler E, Hogdal L, Prasetyanti PR, Grandela CM, Letai A & Medema JP (2014) Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells. Cell Death Differ 21, 1170-1177.
61. Ma S, Lee TK, Zheng BJ, Chan KW & Guan XY (2008) CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27, 1749-1758.
62. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S et al. (2009) Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 106, 16281-16286.
63. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C & De Maria R (2006) Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 13, 1238-1241.
64. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum D et al. (2010) CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Investig 120, 485-497.
65. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G, Medema JP et al. (2007) Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1, 389-402.
66. Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J, Ngan L, Pickell K, Aguilar J, Lazetic S, Smith-Berdan S et al. (2008) Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 3, e2428.
67. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, Nakamura R, Tanaka T, Tomiyama H, Saito N et al. (2007) Chemotherapy-resistant human AML stem cells home to and engraft within the bonemarrow endosteal region. Nat Biotechnol 25, 1315-1321.
68. Baumann M, Krause M & Hill R (2008) Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 8, 545-554.
69. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M et al. (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458, 780-783.
70. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG & Parada LF (2012) A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488, 522-526.
71. Wilson BJ, Schatton T, Zhan Q, Gasser M, Ma J, Saab KR, Schanche R, Waaga-Gasser AM, Gold JS, Huang Q et al. (2011) ABCB5 identifies a therapyrefractory tumor cell population in colorectal cancer patients. Cancer Res 71, 5307-5316.
72. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC et al. (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100, 672-679.
73. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J et al. (2007) let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131, 1109-1123.
74. Tamura K, Aoyagi M, Wakimoto H, Ando N, Nariai T, Yamamoto M & Ohno K (2010) Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation. J Neurosurg 113, 310-318.
75. Tait SW & Green DR (2010) Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 11, 621-632.
76. Madjd Z, Mehrjerdi AZ, Sharifi AM, Molanaei S, Shahzadi SZ & Asadi-Lari M (2009) CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours. Cancer Immun 9, 4.
77. Konopleva M, Zhao S, Hu W, Jiang S, Snell V, Weidner D, Jackson CE, Zhang X, Champlin R, Estey E et al. (2002) The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. Br J Haematol 118, 521-534.
78. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL & Yu JS (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5, 67.
79. Van Houdt WJ, Emmink BL, Pham TV, Piersma SR, Verheem A, Vries RG, Fratantoni SA, Pronk A, Clevers H, Borel Rinkes IH et al. (2011) Comparative proteomics of colon cancer stem cells and differentiated tumor cells identifies BIRC6 as a potential therapeutic target. Mol Cell Proteomics 10, M111 011353.
80. Del Gaizo Moore V & Letai A (2013) BH3 profiling-measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett 332, 202-205.
81. de Grouw EP, Raaijmakers MH, Boezeman JB, van der Reijden BA, van de Locht LT, de Witte TJ, Jansen JH & Raymakers RA (2006) Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34+CD38-cells. Leukemia 20, 750-754.
82. Shervington A & Lu C (2008) Expression of multidrug resistance genes in normal and cancer stem cells. Cancer Invest 26, 535-542.
83. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C et al. (2008) Identification of cells initiating human melanomas. Nature 451, 345-349.
84. Emmink BL, Van Houdt WJ, Vries RG, Hoogwater FJ, Govaert KM, Verheem A, Nijkamp MW, Steller EJ, Jimenez CR, Clevers H et al. (2011) Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan. Gastroenterology 141, 269-278.
85. Gao MQ, Choi YP, Kang S, Youn JH & Cho NH (2010) CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 29, 2672-2680.
86. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T & Herlyn M (2010) A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141, 583-594.
87. Dembinski JL & Krauss S (2009) Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. Clin Exp Metastasis 26, 611-623.
88. Signore M, Pelacchi F, di Martino S, Runci D, Biffoni M, Giannetti S, Morgante L, De Majo M, Petricoin EF, Stancato L et al. (2014) Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. Cell Death Dis 5, e1223.
89. Bartucci M, Svensson S, Romania P, Dattilo R, Patrizii M, Signore M, Navarra S, Lotti F, Biffoni M, Pilozzi E et al. (2012) Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. Cell Death Differ 19, 768-778.
90. Niida H, Tsuge S, Katsuno Y, Konishi A, Takeda N & Nakanishi M (2005) Depletion of Chk1 leads to premature activation of Cdc2-cyclin B and mitotic catastrophe. J Biol Chem 280, 39246-39252.
91. Sausville E, Lorusso P, Carducci M, Carter J, Quinn MF, Malburg L, Azad N, Cosgrove D, Knight R, Barker P et al. (2014) Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemother Pharmacol 73, 539-549.
92. Mir SE, De Witt Hamer PC, Krawczyk PM, Balaj L, Claes A, Niers JM, Van Tilborg AA, Zwinderman AH, Geerts D, Kaspers GJ et al. (2010) In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 18, 244-257.
93. Kemper K, Rodermond H, Colak S, Grandela C & Medema JP (2012) Targeting colorectal cancer stem cells with inducible caspase-9. Apoptosis 17, 528-537.
94. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681.
95. Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, Tulpule A, Dunleavy K, Xiong H, Chiu YL et al. (2010) Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 11, 1149-1159.
96. Zeuner A, Francescangeli F, Contavalli P, Zapparelli G, Apuzzo T, Eramo A, Baiocchi M, De Angelis ML, Biffoni M, Sette G et al. (2014) Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-X inhibition in non-small cell lung cancer. Cell Death Differ. doi:10.1038/cdd.2014.105.
97. Swaminathan SK, Roger E, Toti U, Niu L, Ohlfest JR & Panyam J (2013) CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release 171, 280-287.
98. Damek-Poprawa M, Volgina A, Korostoff J, Sollecito TP, Brose MS, O'Malley BW Jr, Akintoye SO & DiRienzo JM (2011) Targeted inhibition of CD133+ cells in oral cancer cell lines. J Dent Res 90, 638-645.
99. Bach P, Abel T, Hoffmann C, Gal Z, Braun G, Voelker I, Ball CR, Johnston IC, Lauer UM, Herold-Mende C et al. (2013) Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus. Cancer Res 73, 865-874.
100. Wang CH, Chiou SH, Chou CP, Chen YC, Huang YJ & Peng CA (2011) Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody. Nanomedicine 7, 69-79.
101. Bostad M, Berg K, Hogset A, Skarpen E, Stenmark H & Selbo PK (2013) Photochemical internalization (PCI) of immunotoxins targeting CD133 is specific and highly potent at femtomolar levels in cells with cancer stem cell properties. J Control Release 168, 317-326.
102. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, van Rooijen N & Weissman IL (2009) CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286-299.
103. Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD et al. (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 109, 6662-6667.
104. Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, Apuzzo T, Sperduti I, Volpe S, Cocorullo G et al. (2014) CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 14, 342-356.
105. Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, Lagoo A & Reya T (2007) Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 12, 528-541.
106. Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, Zon LI & Armstrong SA (2010) The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 327, 1650-1653.
107. Heidel FH, Bullinger L, Feng Z, Wang Z, Neff TA, Stein L, Kalaitzidis D, Lane SW & Armstrong SA (2012) Genetic and pharmacologic inhibition of betacatenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell 10, 412-424.
108. McAuliffe SM, Morgan SL, Wyant GA, Tran LT, Muto KW, Chen YS, Chin KT, Partridge JC, Poole BB, Cheng KH et al. (2012) Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci USA 109, E2939-E2948.
109. Kobune M, Takimoto R, Murase K, Iyama S, Sato T, Kikuchi S, Kawano Y, Miyanishi K, Sato Y, Niitsu Y et al. (2009) Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells. Cancer Sci 100, 948-955.
110. Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, Huber S, Ellwart JW, Mustafa M, Bartenstein P, D'Haese JG et al. (2009) Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 137, 1102-1113.
111. Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W, Piccirillo S, Vescovi AL, DiMeco F, Olivi A et al. (2007) Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 25, 2524-2533.
112. Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J, Kwon HY, Kim J, Chute JP, Rizzieri D et al. (2009) Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458, 776-779.
113. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M et al. (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11, 69-82.
114. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F & Dick JE (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12, 1167-1174.
115. Lombardo Y, Scopelliti A, Cammareri P, Todaro M, Iovino F, Ricci-Vitiani L, Gulotta G, Dieli F, de Maria R & Stassi G (2011) Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology 140, 297-309.
116. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, Brem H, Olivi A, Dimeco F & Vescovi AL (2006) Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444, 761-765.
117. Heijmans J, van Lidth de Jeude JF, Koo BK, Rosekrans SL, Wielenga MC, van de Wetering M, Ferrante M, Lee AS, Onderwater JJ, Paton JC et al. (2013) ER stress causes rapid loss of intestinal epithelial stemness through activation of the unfolded protein response. Cell Rep 3, 1128-1139.